Jutta Stoffers-Winterling

Jutta Stoffers-Winterling

Auto-generated profile, based on publicly available information

Jutta Stoffers-Winterling

Leibniz Institute for Resilience Research, Mainz, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2020 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
OSOle Jakob Storebø
Ole Jakob Storebø
JSJutta M Stoffers-Winterling
Jutta M Stoffers-Winterling
BVBirgit A Völlm
Birgit A Völlm
MKMickey T Kongerslev
Mickey T Kongerslev
JMJessica T Mattivi
Jessica T Mattivi
ESErik Simonsen
Erik Simonsen

2 January 2010 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
KLKlaus Lieb
Klaus Lieb
BVBirgit Völlm
Birgit Völlm
GRGerta Rucker
Gerta Rucker
ATAntje Timmer
Antje Timmer
JSJutta M. Stoffers
Jutta M. Stoffers
Background: Many patients with borderline personality disorder receive pharmacological treatment, but there is uncertainty about the usefulness of such therapies.Aims: To evaluate the evidence of effectiveness of pharmacotherapy in treating different facets of the psychopathology of borderline personality disorder.Method: A Cochrane Collaboration systematic review and meta-analysis of randomised comparisons of drug v. placebo, drug v. drug, or single drug v. combined drug treatment in adult patients with borderline personality disorder was conducted. Primary outcomes were overall disorder severity as well as specific core symptoms. Secondary outcomes comprised associated psychiatric pathology and drug tolerability.Results: Twenty-seven trials were included in which first- and second-generation antipsychotics, mood stabilisers, antidepressants and omega-3 fatty acids were tested. Most beneficial effects were found for the mood stabilisers topiramate, lamotrigine and valproate semisodium, and the second-generation antipsychotics aripiprazole and olanzapine. However, the robustness of findings is low, since they are based mostly on single, small studies. Selective serotonin reuptake inhibitors so far lack high-level evidence of effectiveness.Conclusions: The current evidence from randomised controlled trials suggests that drug treatment, especially with mood stabilisers and second-generation antipsychotics, may be effective for treating a number of core symptoms and associated psychopathology, but the evidence does not currently support effectiveness for overall severity of borderline personality disorder. Pharmacotherapy should therefore be targeted at specific symptoms.

15 August 2012 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
JSJutta M Stoffers-Winterling
Jutta M Stoffers-Winterling
BVBirgit A Völlm
Birgit A Völlm
GRGerta Rucker
Gerta Rucker
ATAntje Timmer
Antje Timmer
NHNick Huband
Nick Huband
KLKlaus Lieb
Klaus Lieb

16 June 2010 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
JSJutta Stoffers
Jutta Stoffers
BVBirgit A Völlm
Birgit A Völlm
GRGerta Rucker
Gerta Rucker
ATAntje Timmer
Antje Timmer
NHNick Huband
Nick Huband
KLKlaus Lieb
Klaus Lieb

28 January 2022 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
JSJutta M. Stoffers-Winterling
Jutta M. Stoffers-Winterling
OSOle Jakob Storebø
Ole Jakob Storebø
MKMickey T. Kongerslev
Mickey T. Kongerslev
EFErlend Faltinsen
Erlend Faltinsen
ATAdan Todorovac
Adan Todorovac
ESErik Simonsen
Erik Simonsen
Background: A recently updated Cochrane review supports the efficacy of psychotherapy for borderline personality disorder (BPD).Aims: To evaluate the effects of standalone and add-on psychotherapeutic treatments more concisely.Method: We applied the same methods as the 2020 Cochrane review, but focused on adult samples and comparisons of active treatments and unspecific control conditions. Standalone treatments (i.e. necessarily including individual psychotherapy as either the sole or one of several treatment components) and add-on interventions (i.e. complementing any ongoing individual BPD treatment) were analysed separately. Primary outcomes were BPD severity, self-harm, suicide-related outcomes and psychosocial functioning. Secondary outcomes were remaining BPD diagnostic criteria, depression and attrition.Results: Thirty-one randomised controlled trials totalling 1870 participants were identified. Among standalone treatments, statistically significant effects of low overall certainty were observed for dialectical behaviour therapy (self-harm: standardised mean difference (SMD) −0.54, P = 0.006; psychosocial functioning: SMD −0.51, P = 0.01) and mentalisation-based treatment (self-harm: risk ratio 0.51, P < 0.0007; suicide-related outcomes: risk ratio 0.10, P < 0.0001). For adjunctive interventions, moderate-quality evidence of beneficial effects was observed for DBT skills training (BPD severity: SMD −0.66, P = 0.002; psychosocial functioning: SMD −0.45, P = 0.002), and statistically significant low-certainty evidence was observed for the emotion regulation group (BPD severity: mean difference −8.49, P < 0.00001), manual-assisted cognitive therapy (self-harm: mean difference −3.03, P = 0.03; suicide-related outcomes: SMD −0.96, P = 0.005) and the systems training for emotional predictability and problem-solving (BPD severity: SMD −0.48, P = 0.002).Conclusions: There is reasonable evidence to conclude that psychotherapeutic interventions are helpful for individuals with BPD. Replication studies are needed to enhance the certainty of findings.

21 November 2014 in Current Psychiatry Reports
Verified
Journal Article
Closed access
PDF file
JSJutta M. Stoffers
Jutta M. Stoffers
KLKlaus Lieb
Klaus Lieb